Arcus Biosciences, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Arcus Biosciences, Inc. (RCUS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $15.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- Arcus Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $15.00M, a 0.00% change year-over-year.
- Arcus Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $19.00M, a 18.75% increase year-over-year.
- Arcus Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $14.00M, a 26.32% decline year-over-year.
- Arcus Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $15.00M, a 25.00% decline year-over-year.
- Arcus Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $60.00M, a 21.05% decline from fiscal 2024.
- Arcus Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $76.00M, a 4.11% increase from fiscal 2023.
- Arcus Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $73.00M, a 12.31% increase from fiscal 2022.
- Arcus Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $65.00M, a 18.18% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $15.00M 10-Q · filed 2026-08-05 | $34.00M derived: sum of 2 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $19.00M 10-Q · filed 2026-08-05 | |||||
| 2025-12-31 | $60.00M 10-K · filed 2026-02-25 | |||||
| 2025-09-30 | $14.00M 10-Q · filed 2025-10-28 | $29.00M derived: sum of 2 quarters · filed 2026-08-05 | $45.00M derived: sum of 3 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $15.00M 10-Q · filed 2026-08-05 | $31.00M derived: sum of 2 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $16.00M 10-Q · filed 2026-08-05 | |||||
| 2024-12-31 | $76.00M 10-K · filed 2026-02-25 | |||||
| 2024-09-30 | $19.00M 10-Q · filed 2025-10-28 | $39.00M derived: sum of 2 quarters · filed 2025-10-28 | $59.00M derived: sum of 3 quarters · filed 2025-10-28 | |||
| 2024-06-30 | $20.00M 10-Q · filed 2025-10-28 | $40.00M derived: sum of 2 quarters · filed 2025-10-28 | ||||
| 2024-03-31 | $20.00M 10-Q · filed 2025-10-28 | |||||
| 2023-12-31 | $73.00M 10-K · filed 2026-02-25 | |||||
| 2023-09-30 | $18.00M 10-Q · filed 2024-11-06 | $36.00M derived: sum of 2 quarters · filed 2024-11-06 | $55.00M derived: sum of 3 quarters · filed 2024-11-06 | |||
| 2023-06-30 | $18.00M 10-Q · filed 2024-11-06 | $37.00M derived: sum of 2 quarters · filed 2024-11-06 | ||||
| 2023-03-31 | $19.00M 10-Q · filed 2024-11-06 | |||||
| 2022-12-31 | $65.00M 10-K · filed 2025-02-25 | |||||
| 2022-09-30 | $16.00M 10-Q · filed 2023-11-07 | $16.26M 10-Q · filed 2022-11-02 | $31.00M derived: sum of 2 quarters · filed 2023-11-07 | $48.00M derived: sum of 3 quarters · filed 2023-11-07 | ||
| 2022-06-30 | $15.00M 10-Q · filed 2023-11-07 | $15.68M 10-Q · filed 2022-08-03 | $32.00M derived: sum of 2 quarters · filed 2023-11-07 | |||
| 2022-03-31 | $17.00M 10-Q · filed 2023-11-07 | $16.54M 10-Q · filed 2022-05-09 | ||||
| 2021-12-31 | $55.00M 10-K · filed 2024-02-21 | $54.53M 10-K · filed 2022-02-23 | ||||
| 2021-09-30 | $14.59M 10-Q · filed 2022-11-02 | $27.95M derived: sum of 2 quarters · filed 2022-11-02 | $40.71M derived: sum of 3 quarters · filed 2022-11-02 | |||
| 2021-06-30 | $13.37M 10-Q · filed 2022-11-02 | $26.13M derived: sum of 2 quarters · filed 2022-11-02 | ||||
| 2021-03-31 | $12.76M 10-Q · filed 2022-11-02 | |||||
| 2020-12-31 | $22.00M 10-K · filed 2023-02-28 | $21.82M 10-K · filed 2021-02-25 | ||||
| 2020-09-30 | $6.00M 10-Q · filed 2021-11-08 | $10.47M derived: sum of 2 quarters · filed 2021-11-08 | $13.93M derived: sum of 3 quarters · filed 2021-11-08 | |||
| 2020-06-30 | $4.47M 10-Q · filed 2021-11-08 | $7.93M derived: sum of 2 quarters · filed 2021-11-08 | ||||
| 2020-03-31 | $3.46M 10-Q · filed 2021-11-08 | |||||
| 2019-12-31 | $8.98M 10-K · filed 2022-02-23 | |||||
| 2019-09-30 | $2.74M 10-Q · filed 2020-11-05 | $4.87M derived: sum of 2 quarters · filed 2020-11-05 | $6.54M derived: sum of 3 quarters · filed 2020-11-05 | |||
| 2019-06-30 | $2.13M 10-Q · filed 2020-11-05 | $3.80M derived: sum of 2 quarters · filed 2020-11-05 | ||||
| 2019-03-31 | $1.67M 10-Q · filed 2020-11-05 | |||||
| 2018-12-31 | $3.87M 10-K · filed 2021-02-25 | |||||
| 2018-09-30 | $1.05M 10-Q · filed 2019-11-05 | $2.16M derived: sum of 2 quarters · filed 2019-11-05 | $2.82M derived: sum of 3 quarters · filed 2019-11-05 | |||
| 2018-06-30 | $1.12M 10-Q · filed 2019-11-05 | $1.77M derived: sum of 2 quarters · filed 2019-11-05 | ||||
| 2018-03-31 | $656.00K 10-Q · filed 2019-11-05 | |||||
| 2017-12-31 | $495.00K 10-K · filed 2019-03-05 | |||||
| 2016-12-31 | $90.00K 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |